Canopus secures WARF patents

Canopus BioPharma, Inc., a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer and addiction, has signed a licensing agreement with the Wisconsin Alumni Research Foundation (WARF), an organisation serving the University of Wisconsin-Madison scientific community by patenting the discoveries of UW-Madison researchers and licensing these technologies to companies worldwide.

The agreement provides comprehensive licensing rights and patent protection relating to Canopus' Phase II oncology drug candidate, CB1400.

"Securing the rights to the WARF patents strengthens Canopus BioPharma's intellectual property position for future licensing opportunities of CB1400, one of our most exciting products," said Patrick Prendergast, chairman and

CEO of Canopus BioPharma. "In the near future, we expect to announce important results from our studies using CB1400, which will further validate the potential significance of our drug for oncology and related indications."

Print | Email | Discuss this article |

READERS' COMMENTS

View all comments (0)

Have your say

Click here to post a comment

Add your Comment All posts are sent to the administrator for review and are published only after approval. ArabianBusiness.com reserves the right to remove any comment at any time for any reason. Please keep your responses appropriate and on topic.
Name *
Remember me on this computer
Email *	(Your email address will not be published)
City
Country
Subject *
Comment *
Notify me of further comments
Security Code *
Please click post only once - your comment will not be published immediately.

MORE FROM ARABIANBUSINESS.COM